# Author Index for Volume 8


Andersen PK, 67
Atkinson EN, 29
Azen SP, 354

Baglivo J, 243
Begg CB, 121
Bissett JK, 136
Blankenhorn DH, 354
Blessing JA, 60
Brown BW, 29
Brown BW Jr, 177
Brown ER, 243
Bundy BN, 60

Canner PL, 1
Case LD, 146
Chalmers I, 388
Chalmers TC, 343
Chan S, 343
Charboneau A, 190
CLAS Investigators and Staff, 354
Curb JD, 110

Dantes R, 12
Davis BR, 110
Davis CE, 146
Detre K, 190
Dickersin K, 343
Dyrda I, 216

Edler L, 45
Ehrman S, 110

Farmer J, 110
Foulkes MA, 315
Freedman D, 216
Fye CL, 101

Gatewood LC, 1
Goldman AI, 327
Gosselin G, 216

Haakenson C, 101
Hache M, 216
Halloran J, 216
Halperin M, 315
Halpern J, 177
Hamersma, EAM, 96
Hatch HT, 190
Havel RJ, 216
Hawkins BS, 75, 158, 255, 395
Hawkins CM, 110
Haynes RB, 12
Heiselbetz C, 45
Herson J, 29
Hudon G, 216

Johnson G, 190
Johnson RL, 354
Joyal M, 216

Kalish LA, 121
Kamm B, 216
Karnegis JN, 136
Krishnamoorthy KC, 243
Kuban KCK, 243

Lachin JM, 1
Lan KKG, 315
Langley GR, 49
Lemarbre L, 216
Leon AS, 136
Lesperance J, 216
Leviton A, 243
Llewellyn-Thomas HA, 49
Long JM, 136

Martin M, 110
Matts JP, 136
Minkin S, 49
Morgan TM, 146

Nessim SA, 354

Patterson BH, 87, 202
Peduzzi P, 190
Phillips M, 338
Piantadosi S, 202
Priore RL, 60
Pritchett J, 190

Reese PA, 60
Rozell ME, 29

Sacks HS, 343
Sanmarco ME, 354
Sather MR, 101
Sawin HS, 136
Schoenfield LJ, 1
Selzer RH, 354
Siers A, 96
Silverman W, 388
Slagle JR, 136
Smith H Jr, 343
Stevenson JP, 136
Sutherland HJ, 49

Therneau T, 20
Theroux P, 216
Till JE, 49
Toussaint DJ, 101
Tung B, 110

van der Putten E, 96
van der Velden JW, 96
Vazquez AJ, 338

Waters D, 216
White C, 1
Wick MW, 136
Wieand S, 20
Wong S, 49
Wright EC, 315


© Elsevier Science Publishing Co., Inc. 1987
52 Vanderbilt Ave., New York, New York 10017



0197-2456/87/$3.50

# Subject Index for Volume 8


**ABNORMAL FINDINGS IN "NORMAL" VOLUNTEERS**
Abnormal Findings in "Normal" Research Volunteers, 338

**ACCRUAL**
A Method for Predicting Accrual, Cost, and Paper Flow in Clinical Trials, 202

**APL**
A Sample Size Program for "Proving the Null Hypothesis," 45

**ARCSIN STATIC**
A Two-Stage Design for Randomized Trials with Binary Outcomes, 20

**BAYESIAN METHODS**
Projection from Previous Studies: A Bayesian and Frequentist Compromise, 29

**BENEFICIARY IDENTIFICATION**
Coordinating Center Follow-up in the Veterans Administration Cooperative Study of Coronary Artery Bypass Surgery, 190

**BINOMIAL RESPONSE**
A Two-Stage Design for Randomized Trials with Binary Outcomes, 20

**BOOK REVIEWS**
*A Classified Bibliography of Controlled Trials in Perinatal Medicine, 1940–1984* by the National Perinatal Epidemiology Unit (Oxford, England), 85
*Clinical Epidemiology. The Architecture of Clinical Research* by Feinstein AR, 404
*Clinical Trials: Design, Conduct, and Analysis* by Meinert CL in collaboration with Tonascio S, 406
*The Quality of Life of Cancer Patients*, Aaronson NK and Beckmann J (eds.), 409

**CANCER CLINICAL TRIAL**
A Pilot Study on the Quality of Data Management in a Cancer Clinical Trial, 96

**CENSORED SURVIVAL DATA**
Conditional Power Calculations as an Aid in the Decision Whether to Continue a Clinical Trial, 67

**CENTRALIZED FOLLOW-UP**
Coordinating Center Follow-up in the Veterans Administration Cooperative Study of Coronary Bypass Surgery, 190

**CLINICAL EXPERIMENTATION**
Professional and Public Double Standards on Clinical Experimentation, 388

**CLINICAL JUDGMENT**
An Example of Expert Systems Applied to Clinical Trials: Analysis of Serial Graded Exercise ECG Test Data, 136

**CLINICAL TRIALS**
Cholesterol Lowering Atherosclerosis Study (CLAS): Design, Methods, and Baseline Results, The, 354
Example of Expert Systems Applied to Clinical Trials: Analysis of Serial Graded Exercise ECG Test Data, An, 136
Experience with the Use of Generalized Data Base Management Systems in Cooperative Group Clinical Trials (A Project of the Gynecologic Oncology Group), 60
External Monitoring of a Data Coordinating Center: Experience of the National Cooperative Gallstone Study, 1
Investigator-Sponsored IND in Clinical Trials, The, 101
Method for Predicting Accrual, Cost, and Paper Flow in Clinical Trials, A, 202
Optimal Restricted Two-Stage Designs, 146
Patient Compliance and the Conduct and Interpretation of Therapeutic Trials, 12
Prophylactic Clinical Trial as an Epidemiologic Resource, The, 243
Stochastic Curtailing for Comparison of Slopes in Longitudinal Studies, 315



0197-2456/87/$3.50

© Elsevier Science Publishing Co., Inc. 1987
52 Vanderbilt Ave., New York, New York 10017

Why Are (or Are Not) Patients Given the Option to Enter Clinical Trials?, 49

**CLINICAL TRIAL DESIGN**
Designing Clinical Trials with Arbitrary Specification of Survival Functions and for the Log Rank or Generalized Wilcoxon Test, 177

**CODING CAUSE OF DEATH**
Standardized Physician Preparation of Death Certificates, 110

**COMMENTARY**
Professional and Public Double Standards on Clinical Experimentation, 388

**COORDINATING CENTER**
Coordinating Center Follow-up in the Veterans Administration Cooperative Study of Coronary Artery Bypass Surgery, 190

**COMPUTER PROGRAM**
A Sample Size Program for "Proving the Null Hypothesis," 45

**COMPUTERIZED ASSESSMENT OF ATHEROSCLEROSIS**
The Cholesterol Lowering Atherosclerosis Study (CLAS): Design, Methods, and Baseline Results, 354

**CONDITIONAL CONFIDENCE INTERVALS**
Conditional Power Calculations as an Aid in the Decision Whether to Continue a Clinical Trial, 67

**COOPERATIVE GROUP**
Experience with the Use of Generalized Data Base Management Systems in Cooperative Group Clinical Trials (A Project of the Gynecologic Oncology Group), 60

**CORONARY ANGIOGRAPHY**
The Cholesterol Lowering Atherosclerosis Study (CLAS): Design, Methods, and Baseline Results, 354

**CORONARY ARTERY DISEASE**
Design Features of a Controlled Clinical Trial To Assess the Effect of A Calcium Entry Blocker Upon the Progression of Coronary Artery Disease, 216

**COST**
A Method for Predicting Accrual, Cost, and Paper Flow in Clinical Trials, 202

**COST MODEL**
The Impact of Screening and Eliminating Preexisting Cases on Sample Size Requirements for Cancer Prevention Trials, 87

**CURE RATE MODEL**
Designing Clinical Trials with Arbitrary Specification of Survival Functions and for the Log Rank or Generalized Wilcoxon Test, 177

**DATA ANALYSIS**
An Example of Expert Systems Applied to Clinical Trials: Analysis of Serial Graded Exercise ECG Test Data, 136

**DATA COORDINATING CENTER**
External Monitoring of a Data Coordinating Center: Experience of the National Cooperative Gallstone Study, 1

**DATA MANAGEMENT**
A Pilot Study on the Quality of Data Management in a Cancer Clinical Trial, 96

**DATABASE MANAGEMENT SYSTEM**
Experience with the Use of Generalized Data Base Management Systems in Cooperative Group Clinical Trials (A Project of the Gynecologic Oncology Group), 60

**DEATH CERTIFICATES**
Standardized Physician Preparation of Death Certificates, 110

**DESIGN**
A Sample Size Program for "Proving the Null Hypothesis," 45

**EPIDEMIOLOGY**
The Prophylactic Clinical Trial as an Epidemiologic Resource, 243

**EQUIVALENCE TESTING**
A Sample Size Program for "Proving the Null Hypothesis," 45

**ETHICS**
Why Are (or Are Not) Patients Given the Option to Enter Clinical Trials?, 49

**EXPERT SYSTEMS**
An Example of Expert Systems Applied to Clinical Trials: Analysis of Serial Graded Exercise ECG Test Data, 136

**FEMORAL ANGIOGRAPHY**
The Cholesterol Lowering Atherosclerosis Study (CLAS): Design, Methods, and Baseline Results, 354

**FOOD AND DRUG ADMINISTRATION**
The Investigator-Sponsored IND in Clinical Trials, 101

**GENERALIZED WILCOXON TEST**
Designing Clinical Trials with Arbitrary Specification of Survival Functions and for the Log Rank or Generalized WilcoxonTest, 177

**IND**
The Investigator-Sponsored IND in Clinical Trails, 101

**INVESTIGATOR**
The Investigator-Sponsored IND in Clinical Trials, 101

**LINEAR REGRESSION**
Stochastic Curtailing for Comparison of Slopes in Longitudinal Studies, 315

**LITERATURE**
Perusing the Literature, 75, 158, 255, 395

**LOG RANK TEST**
Designing Clinical Trials with Arbitrary Specification of Survival Functions and for the Log Rank or Generalized Wilcoxon Test, 177

**LOGISTIC MODEL**
The Impact of Treatment Allocation Procedures on Nominal Significance Levels and Bias, 121

**MATHEMATICAL MODELS**
A Method for Predicting Accrual, Cost, and Paper Flow in Clinical Trials, 202

**META-ANALYSIS**
Publication Bias and Clinical Trials, 343

**MONITORING**
External Monitoring of a Data Coordinating Center: Experience of the National Cooperative Gallstone Study, 1

**NOMINAL SIGNIFICANCE LEVEL**
The Impact of Treatment Allocation Procedures on Nominal Significance Levels and Bias, 121

**NOSOLOGICAL CODING**
Standardized Physician Preparation of Death Certificates, 110

**ONCOLOGY**
Why Are (or Are Not) Patients Given the Option to Enter Clinical Trials?, 49

**PATIENT COMPLIANCE**
Patient Compliance and the Conduct and Interpretation of Therapeutic Trials, 12

**PATIENT TREATMENT FILE**
Coordinating Center Follow-up in the Veterans Administration Cooperative Study of Coronary Artery Bypass Surgery, 190

**PERMUTATION TEST**
The Impact of Treatment Allocation Procedures on Nominal Significance Levels and Bias, 121

**PREVENTION**
The Prophylactic Clinical Trial as an Epidemiological Resource, 243

**PREVENTION TRIAL**
The Impact of Screening and Eliminating Preexisting Cases on Sample Size Requirements for Cancer Prevention Trials, 87

**PUBLICATION BIAS**
Publication Bias and Clinical Trials, 343

**QUALITY CONTROL**
A Pilot Study on the Quality of Data Management in a Cancer Clinical Trial, 96

**RANDOM ALLOCATION**
Patient Compliance and the Conduct and Interpretation of Therapeutic Trials, 12

**RANDOMIZATION**
The Impact of Treatment Allocation Procedures on Nominal Significance Levels and Bias, 121

**RANDOMIZED CLINICAL TRIALS**
Publication Bias and Clinical Trails, 343

**RECORDS LOCATOR SUBSYSTEM**
Coordinating Center Follow-up in the Veterans Administration Cooperative Study of Coronary Bypass Surgery, 190

**SAMPLE SIZE**
Impact of Screening and Eliminating Preexisting Cases on Sample Size Requirements for Cancer Prevention Trails, The, 87
Optimal Restricted Two-Stage Designs, 146
Projection from Previous Studies: A Bayesian and Frequentist Compromise, 29
Sample Size Program for "Proving the Null Hypothesis," A, 45

**SCREENING**
The Impact of Screening and Eliminating Preexisting Cases on Sample Size Requirements for Cancer Prevention Trials, 87

**SEQUENTIAL STOPPING RULES**
Issues in Designing Sequential Stopping Rules for Monitoring Side Effects in Clinical Trials, 327

**SIDE EFFECTS**
Issues in Designing Sequential Stopping Rules for Monitoring Side Effects in Clinical Trials, 327

**SOCIETY FOR CLINICAL TRIALS**
Abstracts: Eighth Annual Meeting Society for Clinical Trails, 280
Final Program: Eighth Annual Meeting Society for Clinical Trials, 267
Society for Clinical Trials Officers, Board of Directors, Program Committee, and Secretariat, 266

**SPONSOR**
The Investigator-Sponsored IND in Clinical Trials, 101

**STOCHASTIC CURTAILING**
Stochastic Curtailing for Comparison of Slopes in Longitudinal Studies, 315

**STOCHASTICALLY CURTAILED TESTING**
Conditional Power Calculations as an Aid in the Decision Whether to Continue a Clinical Trial, 67

**STOPPING RULE**
A Two-Stage Design for Randomized Trials with Binary Outcomes, 20

**STUDY PLANNING**
Projection from Previous Studies: A Bayesian and Frequentist Compromise, 29

**TREATMENT ALLOCATION**
The Impact of Treatment Allocation Procedures on Nominal Significance Levels and Bias, 121

**TREATMENT OF ATHEROSCLEROSIS**
The Cholesterol Lowering Atherosclerosis Study (CLAS): Design, Methods, and Baseline Results, 354

**TWO-STAGE DESIGN**
Optimal Restricted Two-Stage Designs, 146

**VALIDITY**
Patient Compliance and the Conduct and Interpretation of Therapeutic Trials, 12

**VALUE ASSESSMENTS**
Why Are (or Are Not) Patients Given the Option to Enter Clinical Trials?, 49